Sales were driven by a strong flu season and growth in Asia-Pacific business.
Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
Sales of BioFire FilmArray products accounted for more than half of the growth in the quarter.
BioMérieux sees Qvella's system as complementary to its BioFire FilmArray and will consider adopting Qvella's sample treatment technology.
Researchers found that 98 percent of the identifications the system provided were correct, indicating the usefulness of the platform in clinical mycology.
New investor BioMérieux will explore collaborative opportunities using Qvella's sample treatment technology in complementary markets.
Demand for the BioFire FilmArray panels continued to drive sales in the firm's molecular biology business.
Areas like pharma and food and water testing could prove growth areas for the platform as instrument sales growth slows in the clinic microbiology space.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.
In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.
A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.